• Je něco špatně v tomto záznamu ?

Inducible nitric oxide synthase: Good or bad

M. Lind, A. Hayes, M. Caprnda, D. Petrovic, L. Rodrigo, P. Kruzliak, A. Zulli,

. 2017 ; 93 (-) : 370-375. [pub] 20170624

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024897

Nitric oxide synthases (NOS) are a family of isoforms responsible for the synthesis of the potent dilator nitric oxide (NO). Expression of inducible NOS (iNOS) occurs in conditions of inflammation, and produces large amounts of NO. In pathological conditions iNOS is regarded as a harmful enzyme and is proposed to be a major contributor to diseases of the cardiovascular system such as atherosclerosis. In this review, we address the notion that iNOS is a detrimental enzyme in disease and discuss its potentially beneficial roles. Additionally, we describe other molecules associated with iNOS in diseases such as atherosclerosis, and current research on therapeutic inhibitors tested to reduced pathology associated with cardiovascular diseases (CVD).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024897
003      
CZ-PrNML
005      
20180712094803.0
007      
ta
008      
180709s2017 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2017.06.036 $2 doi
035    __
$a (PubMed)28651238
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Lind, Maggie $u Centre for Chronic Disease (CCD), College of Health & Biomedicine, Victoria University, Melbourne, Victoria, Australia.
245    10
$a Inducible nitric oxide synthase: Good or bad / $c M. Lind, A. Hayes, M. Caprnda, D. Petrovic, L. Rodrigo, P. Kruzliak, A. Zulli,
520    9_
$a Nitric oxide synthases (NOS) are a family of isoforms responsible for the synthesis of the potent dilator nitric oxide (NO). Expression of inducible NOS (iNOS) occurs in conditions of inflammation, and produces large amounts of NO. In pathological conditions iNOS is regarded as a harmful enzyme and is proposed to be a major contributor to diseases of the cardiovascular system such as atherosclerosis. In this review, we address the notion that iNOS is a detrimental enzyme in disease and discuss its potentially beneficial roles. Additionally, we describe other molecules associated with iNOS in diseases such as atherosclerosis, and current research on therapeutic inhibitors tested to reduced pathology associated with cardiovascular diseases (CVD).
650    _2
$a zvířata $7 D000818
650    _2
$a kardiovaskulární nemoci $x metabolismus $7 D002318
650    _2
$a lidé $7 D006801
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a synthasa oxidu dusnatého $x metabolismus $7 D019001
650    _2
$a synthasa oxidu dusnatého, typ II $x metabolismus $7 D052247
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hayes, Alan $u Centre for Chronic Disease (CCD), College of Health & Biomedicine, Victoria University, Melbourne, Victoria, Australia.
700    1_
$a Caprnda, Martin $u 1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia.
700    1_
$a Petrovic, Daniel $u Institute of Histology and Embryology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
700    1_
$a Rodrigo, Luis $u Faculty of Medicine, University of Oviedo, Central University Hospital of Asturias (HUCA), Oviedo, Spain.
700    1_
$a Kruzliak, Peter $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic; 2nd Department of Surgery, Centre of Vascular Diseases, Faculty of Medicine, Masaryk University and St. Anne´s Faculty Hospital, Brno, Czech Republic. Electronic address: kruzliakpeter@gmail.com.
700    1_
$a Zulli, Anthony $u Centre for Chronic Disease (CCD), College of Health & Biomedicine, Victoria University, Melbourne, Victoria, Australia. Electronic address: Anthony.Zulli@VU.edu.au.
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 93, č. - (2017), s. 370-375
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28651238 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180712095055 $b ABA008
999    __
$a ok $b bmc $g 1317028 $s 1021818
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 93 $c - $d 370-375 $e 20170624 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace